Compare Merck & Co., Inc. (MRK) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares Silver Trust — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while iShares Silver Trust trades at $60.25. The key difference: Merck & Co., Inc. pays a 2.29% dividend while iShares Silver Trust pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| MRK | SLV | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $105.57 |
52-Week Low | $77.60 | $37.41 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SLV, the iShares Silver Trust ETF, trades at $59.37, down 0.75% on the day, with a bearish technical signal driven by moving averages. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver. Recent news highlights silver's volatility amid Fed policy uncertainty and geopolitical tensions, with institutional buying noted in Q2 2026 filings.
Outlook remains mixed: silver's structural deficit supports prices, but Fed rate risks and dollar fluctuations pose headwinds. Investors face volatility from industrial demand shifts and inflation data, with technical resistance near $60–$61 capping near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
